Annual Report 2019
Division of Cancer Stem Cell
Kenkichi Masutomi, Mitsuhiro Machitani, Mami Yasukawa, Saori Ueki, Michie Yoshikawa
Introduction
Research in the Division of Cancer Stem Cell is focused on deciphering the mechanisms that establish and maintain cancer stem cells and developing novel therapeutic approaches to treat cancer stem cells. In particular, our division studies the molecular links between a) telomerase and RNA-dependent RNA polymerase (RdRP); b) TERT and cancer stem cells; and c) RdRP and anticancer drugs.
Research activities
1. Telomerase and RNA-dependent RNA polymerase
Telomerase is a ribonucleoprotein complex that elongates telomeres. Human telomerase reverse transcriptase (TERT) is known as the catalytic subunit of telomerase and acts as an RNA-dependent DNA polymerase (RdDP), which synthesizes telomere DNA repeats from an RNA template TERC. Although the major function of TERT is believed to be telomere elongation, emerging evidence indicates that TERT exhibits various functions beyond telomere maintenance. We reported that TERT has an RNA-dependent RNA polymerase (RdRP) activity and synthesizes double-stranded RNA (dsRNA) in either a primer-dependent or a primer-independent manner. Moreover, our recent studies have identified that TERT-RdRP activity is regulated by posttranslational modifications.
2. TERT and cancer stem cells
Previous studies indicated that TERT has activities beyond telomere maintenance, and it is speculated that the constitutive expression of TERT not only stabilizes telomere length and facilitates cell immortalization, but also contributes to tumor susceptibility and alters stem cell cycling in vivo even when telomere lengths are not limited. We found that the RdRP activity directly contributes to cancer progression
3. RdRP and anticancer drugs
We further confirmed that the expression levels of TERT protein and the RdRP activities are positively correlated in various human cancer cell lines, indicating that RdRP inhibitors may work effectively for many types of tumors with high levels of TERT expression. We are continuing to discover and characterize novel inhibitors of TERT-RdRP activity as anticancer drugs.
List of papers published in 2019
Journal
1. Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka MS, Kawaji H, Shiozawa K, Machitani M, Abe T, Yamada S, Kaneko MK, Kato Y, Furuta Y, Kondo T, Shirouzu M, Hayashizaki Y, Kaneko S, Masutomi K. CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nat Commun, 11:1557, 2020
2. Maishi N, Kikuchi H, Sato M, Nagao-Kitamoto H, Annan DA, Baba S, Hojo T, Yanagiya M, Ohba Y, Ishii G, Masutomi K, Shinohara N, Hida Y, Hida K. Development of Immortalized Human Tumor Endothelial Cells from Renal Cancer. Int J Mol Sci, 20:Pii: E4595, 2019